AGOMAB THERAPEUTICS NV

AGMBNASDAQ

🏆 #2094 by market capEarnings Mar 3US Equity

$674.28▼ $40.05 (−5.94%)

Simulated price

1h—

24h▼ 5.9%

7d—

14d—

30d—

1y—

🏦Market Cap

$853M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for AGMB.

Trading Snapshot

Day Range: $666.93 – $685.10
52-Week Range: —
Volume: $4.85B
Avg Volume: $5.79B
Shares Outstanding: 49.3M
Next Earnings: Sep 26, 2026

Fundamentals Snapshot

Annual Revenue: $198M
Last Q Revenue: $55M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): —
Dividend Yield: —

Why Investors Own AGMB

✓High-growth profile — revenue up -4.0% YoY with expanding US Equity exposure.
✓Healthy economics — 74% gross margin and 26% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$198M▼ −5.1% YoY

Gross Margin (TTM)

74.0%▲ +1.5% YoY

Operating Income (TTM)

$27M▼ −5.1% YoY

Free Cash Flow (TTM)

$52M▼ −5.1% YoY

About AGOMAB THERAPEUTICS NV

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.

🦦